Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $313000.0.

  • Theravance Biopharma's Other Non-Current Liabilities fell 9371.11% to $313000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $313000.0, marking a year-over-year decrease of 9371.11%. This contributed to the annual value of $1.9 million for FY2024, which is 9762.26% down from last year.
  • Latest data reveals that Theravance Biopharma reported Other Non-Current Liabilities of $313000.0 as of Q3 2025, which was down 9371.11% from $1.5 million recorded in Q2 2025.
  • Theravance Biopharma's Other Non-Current Liabilities' 5-year high stood at $79.5 million during Q4 2023, with a 5-year trough of $313000.0 in Q3 2025.
  • Its 5-year average for Other Non-Current Liabilities is $18.3 million, with a median of $4.9 million in 2024.
  • Per our database at Business Quant, Theravance Biopharma's Other Non-Current Liabilities soared by 230321.96% in 2022 and then plummeted by 9762.26% in 2024.
  • Over the past 5 years, Theravance Biopharma's Other Non-Current Liabilities (Quarter) stood at $75.0 million in 2021, then rose by 1.3% to $76.0 million in 2022, then rose by 4.61% to $79.5 million in 2023, then plummeted by 97.62% to $1.9 million in 2024, then plummeted by 83.44% to $313000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $313000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $1.3 million for Q1 2025.